newsfilter
← Latest News
GlobeNewswire·

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core